Loading paragraph...
Today's Biggest Stock Losers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| SRPT | Sarepta Therapeutics | $16.65 | -$7.80 | -31.90% | 670.6K | $2.4B | $10.42$138.81 |
| AGRZ | Agroz | $2.41 | -$1.08 | -30.83% | 209.7K | $75.6M | $2.40$7.20 |
| ICHR | Ichor | $16.10 | -$6.82 | -29.76% | 138.3K | $786.8M | $13.12$36.48 |
| JELD | Jeld-wen | $3.09 | -$1.12 | -26.55% | 232.2K | $358.7M | $2.32$11.66 |
| FORD | Forward Industries | $10.54 | -$3.44 | -24.61% | 2.4M | $1.2B | $3.32$46.00 |
| ESLA | Estrella Immunopharma | $2.30 | -$0.75 | -24.59% | 767.1K | $113.1M | $0.70$3.15 |
| PMTS | Cpi Card Group | $13.35 | -$4.18 | -23.84% | 259.1K | $198.7M | $12.52$35.19 |
| ADTN | Adtran | $8.06 | -$2.38 | -22.77% | 284.9K | $834.9M | $6.02$12.44 |
| CJET | Chijet Motor | $2.99 | -$0.84 | -21.95% | 244.9K | $350.4M | $2.77$299.00 |
| SONN | Sonnet BioTherapeutics | $3.18 | -$0.85 | -21.09% | 722K | $28.5M | $1.08$19.30 |
Related Articles
Featured Article
Is This Stock a Buy After Soaring by 20% in 1 Day?
Prosper Junior Bakiny|Jul 24, 2025

With Its Kpler Deal on the Rocks, Can Spire Stock Survive?
Rich Smith|Mar 16, 2025
If you pay close enough attention to conference calls, you just might find a stock that can double -- like Spire Global.

After a Big Win, Is Sarepta Therapeutics Stock a Buy?
Alex Carchidi|Jul 6, 2024
One key issue remains unresolved, and it could be a significant one.

Has Sarepta Therapeutics Become a No-Brainer Stock Buy After This Recent FDA News?
David Jagielski|Jul 4, 2024
The label expansion paves the way for much more revenue growth for Sarepta in the years ahead.

1 Soaring Growth Stock to Buy and Hold for 10 Years
Prosper Junior Bakiny|Jul 3, 2024
Let's look beyond the biotech's performance this year.

1 Top Growth Stock to Buy and Hold for 10 Years
Prosper Junior Bakiny|May 1, 2024
This company's lineup might look very different in a decade, but the end result will be the same for investors.

Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
Alex Carchidi|Mar 13, 2024
The threat is still emerging, but it could be significant.

Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst
Alex Carchidi|Mar 4, 2024
The upcoming regulatory decision on its latest drug could be big.

Is It Too Late to Buy Sarepta Therapeutics Stock?
Prosper Junior Bakiny|Feb 28, 2024
The company's hyperfocus on its core area could continue to be highly lucrative.

2 Magnificent Growth Stocks to Buy With $500
Prosper Junior Bakiny|Feb 15, 2024
No need to break the bank to invest in promising stocks.
